| ID Source | ID |
|---|---|
| PubMed CID | 8213 |
| CHEMBL ID | 3188886 |
| SCHEMBL ID | 33335 |
| MeSH ID | M0362654 |
| Synonym |
|---|
| hexadecane, 1-bromo- |
| hexadecyl bromide |
| nsc4193 |
| n-hexadecyl bromide |
| 1-bromohexadecane , |
| n-hexadecyl-1-bromide |
| nsc-4193 |
| 112-82-3 |
| 1-hexadecyl bromide |
| cetyl bromide |
| 1-bromohexadecane, 97% |
| B0599 |
| ec 204-008-7 |
| ai3-11181 |
| einecs 204-008-7 |
| 76gji7gvam , |
| nsc 4193 |
| unii-76gji7gvam |
| dtxsid2049397 , |
| cas-112-82-3 |
| NCGC00260270-01 |
| tox21_202722 |
| dtxcid9029356 |
| FT-0607531 |
| bromohexadecane |
| AKOS015911583 |
| hexadecane,1-bromo- |
| palmityl bromide |
| BR1074 |
| SCHEMBL33335 |
| J-504465 |
| hexadecylbromide |
| CHEMBL3188886 |
| STL453701 |
| hexadecane, bromo- |
| mfcd00000230 |
| D70993 |
| 1-bromohexadecane--d4 |
| hexadecane-1-bromide |
| Q27266490 |
| 1-bromo-hexadecane |
| cetyl bromide, hexadecyl bromide |
| CS-W009341 |
| EN300-83275 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 16.5353 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 13.3418 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1259401 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||